Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Fulcrum Therapeutics, Inc. (FULC)  
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 63,029,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases. Co. has developed a proprietary product engine, FulcrumSeek, that it employs to systematically identify and validate cellular drug targets. Co.' products include: losmapimod, a small molecule that it is developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive and disabling disorder characterized by muscle degeneration and fat infiltration; and FTX-6058, an investigational oral fetal hemoglobin, inducer that is in development for sickle cell disease and select other hemoglobinopathies, including ss-thalassemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 43,360 43,360 43,360 4,472,361
Total Buy Value $492,028 $492,028 $492,028 $39,173,214
Total People Bought 1 1 1 2
Total Buy Transactions 1 1 1 7
Total Shares Sold 5,120 5,120 5,120 150,153
Total Sell Value $59,050 $59,050 $59,050 $1,271,940
Total People Sold 1 1 1 2
Total Sell Transactions 2 2 2 8
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 122
  Page 4 of 5  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Gould Robert J See Remarks   •       •      –    2020-06-01 4 AS $20.00 $100 D/D (5) 549,031     -
   Cadavid Diego SVP Clinical Development   •       –      –    2020-05-29 4 AS $20.04 $4,007 D/D (200) 66,785     -
   Cadavid Diego SVP Clinical Development   •       –      –    2020-05-29 4 OE $4.83 $966 D/D 200 66,985     -
   Gould Robert J See Remarks   •       •      –    2020-05-29 4 AS $20.08 $27,911 D/D (1,390) 549,036     -
   Cadavid Diego SVP Clinical Development   •       –      –    2020-05-28 4 AS $20.00 $12,000 D/D (600) 66,785     -
   Cadavid Diego SVP Clinical Development   •       –      –    2020-05-28 4 OE $4.83 $2,898 D/D 600 67,385     -
   Gould Robert J See Remarks   •       •      –    2020-05-28 4 AS $20.01 $38,391 D/D (1,919) 550,426     -
   Wallace Owen B. Chief Scientific Officer   •       –      –    2020-05-28 4 AS $20.00 $44,640 D/D (2,232) 127,088     -
   Wallace Owen B. Chief Scientific Officer   •       –      –    2020-05-28 4 OE $7.84 $17,499 D/D 2,232 129,320     -
   Wallace Owen B. Chief Scientific Officer   •       –      –    2020-05-27 4 AS $20.00 $8,960 D/D (448) 127,088     -
   Wallace Owen B. Chief Scientific Officer   •       –      –    2020-05-27 4 OE $7.84 $3,512 D/D 448 127,536     -
   Gould Robert J See Remarks   •       •      –    2020-05-26 4 AS $20.00 $50,000 D/D (2,500) 552,345     -
   Wallace Owen B. Chief Scientific Officer   •       –      –    2020-05-26 4 AS $20.00 $8,240 D/D (412) 127,088     -
   Wallace Owen B. Chief Scientific Officer   •       –      –    2020-05-26 4 OE $7.84 $3,230 D/D 412 127,500     -
   Cadavid Diego SVP Clinical Development   •       –      –    2020-05-12 4 AS $18.00 $33,480 D/D (1,860) 66,785     -
   Cadavid Diego SVP Clinical Development   •       –      –    2020-05-12 4 OE $4.83 $8,984 D/D 1,860 68,645     -
   Thomson Peter G. VP Finance & Accounting   •       –      –    2020-05-11 4 AS $16.00 $120,000 D/D (7,500) 21,071     -
   Cadavid Diego SVP Clinical Development   •       –      –    2020-03-02 4 AS $17.26 $37,255 D/D (2,143) 66,785     -
   Thomson Peter G. VP Finance & Accounting   •       –      –    2020-02-24 4 AS $16.18 $84,153 D/D (5,000) 28,571     -
   Wallace Owen B. Chief Scientific Officer   •       –      –    2020-02-19 4 AS $20.00 $121,760 D/D (6,088) 127,088     -
   Wallace Owen B. Chief Scientific Officer   •       –      –    2020-02-19 4 OE $7.84 $47,730 D/D 6,088 133,176     -
   Gould Robert J See Remarks   •       •      –    2020-02-19 4 AS $20.00 $50,000 D/D (2,500) 554,845     -
   Cadavid Diego SVP Clinical Development   •       –      –    2020-02-03 4 AS $17.33 $37,142 D/D (2,143) 68,928     -
   Thomson Peter G. VP Finance & Accounting   •       –      –    2020-01-23 4 AS $17.17 $86,102 D/D (5,000) 33,571     -
   Glaxosmithkline Plc   •       •       •   2019-07-22 4 A $0.00 $0 I/I 1,785,714 1,785,714     -
  122 Records found
  1  2  3  4  5   
  Page 4 of 5
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us